Literature DB >> 20179156

Human accelerated region 1 noncoding RNA is repressed by REST in Huntington's disease.

Rory Johnson1, Nadine Richter, Ralf Jauch, Philip M Gaughwin, Chiara Zuccato, Elena Cattaneo, Lawrence W Stanton.   

Abstract

In the neurons of Huntington's disease (HD) patients, gene regulatory networks are disrupted by aberrant nuclear localization of the master transcriptional repressor REST. Emerging evidence suggests that, in addition to protein-coding genes, noncoding RNAs (ncRNAs) may also contribute to neurodegenerative processes. To discover ncRNAs that are involved in HD, we screened genome-wide data for novel, noncoding targets of REST. This identified human accelerated region 1 (HAR1), a rapidly evolving cis-antisense locus that is specifically transcribed in the nervous system. We show that REST is targeted to the HAR1 locus by specific DNA regulatory motifs, resulting in potent transcriptional repression. Consistent with other REST target genes, HAR1 levels are significantly lower in the striatum of HD patients compared with unaffected individuals. These data represent further evidence that noncoding gene expression changes accompany neurodegeneration in Huntington's disease.

Entities:  

Keywords:  RE1-silencing transcription factor; long noncoding RNA; neurodegeneration; neuron-restrictive silencing factor; regulation

Mesh:

Substances:

Year:  2010        PMID: 20179156     DOI: 10.1152/physiolgenomics.00019.2010

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  52 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  Functions of noncoding RNAs in neural development and neurological diseases.

Authors:  Shan Bian; Tao Sun
Journal:  Mol Neurobiol       Date:  2011-10-04       Impact factor: 5.590

Review 3.  Long non-coding RNAs in corticogenesis: deciphering the non-coding code of the brain.

Authors:  Julieta Aprea; Federico Calegari
Journal:  EMBO J       Date:  2015-10-29       Impact factor: 11.598

Review 4.  Characters, functions and clinical perspectives of long non-coding RNAs.

Authors:  Ruifang Wu; Yuwen Su; Haijing Wu; Yong Dai; Ming Zhao; Qianjin Lu
Journal:  Mol Genet Genomics       Date:  2016-02-17       Impact factor: 3.291

Review 5.  Targeting long non-coding RNA to therapeutically upregulate gene expression.

Authors:  Claes Wahlestedt
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

Review 6.  The Role of Long Noncoding RNAs in Neurodegenerative Diseases.

Authors:  Peixing Wan; Wenru Su; Yehong Zhuo
Journal:  Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.590

Review 7.  Advances in epigenetics and epigenomics for neurodegenerative diseases.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

Review 8.  Non-coding RNA networks underlying cognitive disorders across the lifespan.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Trends Mol Med       Date:  2011-03-15       Impact factor: 11.951

Review 9.  LncRNAs: macromolecules with big roles in neurobiology and neurological diseases.

Authors:  Ye Chen; Jun Zhou
Journal:  Metab Brain Dis       Date:  2017-02-04       Impact factor: 3.584

10.  Diagnosing and Treating Nervous System Disorders by Targeting Novel Classes of Non-coding RNAs.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Int Drug Discov       Date:  2011 Jun-Jul
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.